• 1
    Sarafidis PA, Nilsson PM. The metabolic syndrome: a glance in its history. J Hypertens. 2006. In press.
  • 2
    Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:15951607.
  • 3
    Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med. 1998;15:539553.
  • 4
    Tird Repor. of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:31433421.
  • 5
    Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med. 2002;7:3543.
  • 6
    Lasaridis AN, Sarafidis PA. Diabetic nephropathy and antihypertensive treatment: what are the lessons from clinical trials? Am J Hypertens. 2003;16:689697.
  • 7
    Bakris GL. Protecting renal function in the hypertensive patient: clinical guidelines. Am J Hypertens. 2005;18:112S119S.
  • 8
    Bagby SP. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? J Am Soc Nephrol. 2004;15:27752791.
  • 9
    Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol. 2004;15:27922800.
  • 10
    McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 2001;86:713718.
  • 11
    Cusumano AM, Bodkin NL, Hansen BC. et al. Glomerular hypertrophy is associated with hyperinsulinemia and precedes overt diabetes in aging rhesus monkeys. Am J Kidney Dis. 2002;40:10751085.
  • 12
    Quinones-Galvan A, Ferrannini E. Renal effects of insulin in man. J Nephrol. 1997;10:188191.
  • 13
    Sarafidis PA, Lasaridis AN. Actions of PPARγ agonists explaining a possible blood pressure lowering effect. Am J Hypertens. 2006. In press.
  • 14
    Catalano C, Muscelli E, Quinones GA. et al. Effect of insulin on systemic and renal handling of albumin in nondiabetic and NIDDM subjects. Diabetes. 1997;46:868875.
  • 15
    Sharma AM, Schorr U. Salt sensitivity and insulin resistance: is there a link? Blood Press Suppl. 1996;1:5963.
  • 16
    Galletti F, Strazzullo P, Ferrara I. et al. NaCl sensitivity of essential hypertensive patients is related to insulin resistance. J Hypertens. 1997;15:14851491.
  • 17
    Imanishi M, Yoshioka K, Okumura M. et al. Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care. 2001;24:111116.
  • 18
    Vedovato M, Lepore G, Coracina A, et al. Effect of sodium intake on blood pressure and albuminuria in type 2 diabetic patients: the role of insulin resistance. Diabetologia. 2004;47:300303.
  • 19
    Hall JE, Brands MW, Mizelle HL, et al. Chronic intrarenal hyperinsulinemia does not cause hypertension. Am J Physiol. 1991;260: F663F669.
  • 20
    Sartori C, Scherrer U. Insulin, nitric oxide and the sympathetic nervous system: at the crossroads of metabolic and cardiovascular regulation. J Hypertens. 1999;17:15171525.
  • 21
    Young BA, Johnson RJ, Alpers CE. et al. Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int. 1995;47:935944.
  • 22
    Sowers JR, Draznin B. Insulin, cation metabolism and insulin resistance. J Basic Clin Physiol Pharmacol. 1998;9:223233.
  • 23
    Aron DC, Rosenzweig JL, Abboud HE. Synthesis and binding of insulin-like growth factor I by human glomerular mesangial cells. J Clin Endocrinol Metab. 1989;68:585591.
  • 24
    Conti FG, Striker LJ, Lesniak MA. et al. Studies on binding and mitogenic effect of insulin and insulin-like growth factor I in glomerular mesangial cells. Endocrinology. 1988;122:27882795.
  • 25
    Abrass CK. Diabetic nephropathy. Mechanisms of mesangial matrix expansion. West J Med. 1995;162:318321.
  • 26
    Anderson PW, Zhang XY, Thian J. et al. Insulin and angiotensin II are additive in stimulating TGF-beta 1 and matrix mRNAs in mesangial cells. Kidney Int. 1996;50:745753.
  • 27
    Morrisey K, Evans RA, Wakefield L. et al. Translational regulation of renal proximal tubular epithelial cell transforming growth factor-beta 1 generation by insulin. Am J Pathol. 2001;159:19051915.
  • 28
    Wang S, Denichilo M, Brubaker C. et al. Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int. 2001;60:96105.
  • 29
    Rocchini AP, Moorehead C, DeRemer S, et al. Hyperinsulinemia and the aldosterone and pressor responses to angiotensin II. Hypertension. 1990;15:861866.
  • 30
    Kreisberg JI. Insulin requirement for contraction of cultured rat glomerular mesangial cells in response to angiotensin II: possible role for insulin in modulating glomerular hemodynamics. Proc Natl Acad Sci U S A. 1982;79:41904192.
  • 31
    Ferri C, Pittoni V, Piccoli A. et al. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J Clin Endocrinol Metab. 1995;80:829835.
  • 32
    Piatti PM, Monti LD, Conti M. et al. Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes. 1996;45:316321.
  • 33
    Piatti PM, Monti LD, Galli L. et al. Relationship between endothelin-1 concentration and metabolic alterations typical of the insulin resistance syndrome. Metabolism. 2000;49:748752.
  • 34
    De Mattia G, Cassone-Faldetta M, Bellini C, et al. Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy. Am J Hypertens. 1998;11:983988.
  • 35
    Simonson MS, Herman WH. Protein kinase C and protein tyrosine kinase activity contribute to mitogenic signaling by endothelin-1. Cross-talk between G protein-coupled receptors and pp60c-src. J Biol Chem. 1993;268:93479357.
  • 36
    Fang TC, Wu CC, Huang WC. Inhibition of nitric oxide synthesis accentuates blood pressure elevation in hyperinsulinemic rats. J Hypertens. 2001;19:12551262.
  • 37
    Prabhakar SS. Role of nitric oxide in diabetic nephropathy. Semin Nephrol. 2004;24:333344.
  • 38
    Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol. 2004;286:H1597H1602.
  • 39
    Facchini FS, Hua NW, Reaven GM. et al. Hyperinsulinemia: the missing link among oxidative stress and age-related diseases? Free Radic Biol Med. 2000;29:13021306.
  • 40
    Yaqoob M, McClelland P, Patrick AW. et al. Evidence of oxidant injury and tubular damage in early diabetic nephropathy. QJM. 1994;87:601607.
  • 41
    Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004;65:10091016.
  • 42
    Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Tromb Haemost. 1997;78:656660.
  • 43
    Rerolle JP, Hertig A, Nguyen G, et al. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int. 2000;58:18411850.
  • 44
    Baricos WH. Chronic renal disease: do metalloproteinase inhibitors have a demonstrable role in extracellular matrix accumulation? Curr Opin Nephrol Hypertens. 1995;4:365368.
  • 45
    Niskanen L, Laakso M. Insulin resistance is related to albuminuria in patients with type II (non-insulin-dependent) diabetes mellitus. Metabolism. 1993;42:15411545.
  • 46
    Forsblom CM, Eriksson JG, Ekstrand AV. et al. Insulin resistance and abnormal albumin excretion in non-diabetic first-degree relatives of patients with NIDDM. Diabetologia. 1995;38:363369.
  • 47
    Mykkanen L, Zaccaro DJ, Wagenknecht LE. et al. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes. 1998;47:793800.
  • 48
    De Cosmo S, Minenna A, Ludovico O, et al. Increased urinary albumin excretion, insulin resistance, and related cardiovascular risk factors in patients with type 2 diabetes: evidence of a sex-specific association. Diabetes Care. 2005;28:910915.
  • 49
    Wirta OR, Pasternack AI, Mustonen JT. et al. Urinary albumin excretion rate and its determinants after 6 years in non-insulin-dependent diabetic patients. Nephrol Dial Transplant. 1996;11:449456.
  • 50
    Kim CH, Kim HK, Park JY. et al. Association of microalbuminuria and atherosclerotic risk factors in non-diabetic subjects in Korea. Diabetes Res Clin Pract. 1998;40:191199.
  • 51
    Kim YI, Kim CH, Choi CS. et al. Microalbuminuria is associated with the insulin resistance syndrome independent of hypertension and type 2 diabetes in the Korean population. Diabetes Res Clin Pract. 2001;52:145152.
  • 52
    Hodge AM, Dowse GK, Zimmet PZ. Microalbuminuria, cardiovascular risk factors, and insulin resistance in two populations with a high risk of type 2 diabetes mellitus. Diabet Med. 1996;13:441449.
  • 53
    Pedrinelli R, Dell'Omo G, Penno G, et al. Microalbuminuria, a parameter independent of metabolic influences in hypertensive men. J Hypertens. 2003;21:11631169.
  • 54
    Emoto M, Nishizawa Y, Maekawa K. et al. Insulin resistance in non-obese, non-insulin-dependent diabetic patients with diabetic nephropathy. Metabolism. 1997;46:10131018.
  • 55
    Kobayashi S, Maesato K, Moriya H. et al. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis. 2005;45:275280.
  • 56
    Becker B, Kronenberg F, Kielstein JT. et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol. 2005;16:10911098.
  • 57
    Chen J, Muntner P, Hamm LL. et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol. 2003;14:469477.
  • 58
    Abuaisha B, Kumar S, Malik R. et al. Relationship of elevated urinary albumin excretion to components of the metabolic syndrome in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1998;39:9399.
  • 59
    Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989;149:15141520.
  • 60
    Spangler JG, Konen JC. Hypertension, hyperlipidemia, and abdominal obesity and the development of microalbuminuria in patients with non-insulin-dependent diabetes mellitus. J Am Board Fam Pract. 1996;9:16.
  • 61
    Rowley KG, Iser DM, Best JD. et al. Albuminuria in Australian Aboriginal people: prevalence and associations with components of the metabolic syndrome. Diabetologia. 2000;43:13971403.
  • 62
    Meigs JB, Jacques PF, Selhub J, et al. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. Diabetes Care. 2001;24:14031410.
  • 63
    Hoehner CM, Greenlund KJ, Rith-Najarian S, et al. Association of the insulin resistance syndrome and microalbuminuria among nondiabetic Native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol. 2002;13:16261634.
  • 64
    Jager A, Kostense PJ, Nijpels G. et al. Microalbuminuria is strongly associated with NIDDM and hypertension, but not with the insulin resistance syndrome: the Hoorn Study. Diabetologia. 1998;41:694700.
  • 65
    Srinivasan SR, Myers L, Berenson GS. Risk variables of insulin resistance syndrome in African-American and Caucasian young adults with microalbuminuria: the Bogalusa Heart Study. Am J Hypertens. 2000;13:12741279.
  • 66
    Chen J, Muntner P, Hamm LL. et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167174.
  • 67
    Muntner P, He J, Chen J. et al. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol. 2004;14:686695.
  • 68
    Torn LM, Forsblom C, Fagerudd J. et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care. 2005;28:20192024.
  • 69
    Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:21342140.
  • 70
    Fox CS, Larson MG, Leip EP, et al. Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care. 2005;28:24362440.
  • 71
    Komers R, Anderson S. Paradoxes of nitric oxide in the diabetic kidney. Am J Physiol Renal Physiol. 2003;284:F1121F1137.
  • 72
    Kanauchi M, Kimura K, Akai Y. et al. Insulin resistance and pancreatic beta-cell function in patients with hypertensive kidney disease. Nephrol Dial Transplant. 2004;19:20252029.
  • 73
    Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2005;48:16841699.